GlassScriptPhysician profile
Emily Louise Hall
NPI 1255106415
$908.69
in general payments reported to CMS, 2019-2025
13 companies · $95.00 in 2025
The $95.00 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $814 · 2025: $95.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $56.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.83 |
| Education | $56.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $210.83 | 2024 | |
| Ardelyx, INC. | $168.92 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $129.23 | 2024 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $121.69 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $67.45 | 2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $56.86 | 2024-2025 | Rayaldee |
| Amgen INC. | $35.71 | 2024 | Tavneos |
| Akebia Therapeutics INC | $25.85 | 2024 | Auryxia |
| E.R. Squibb & Sons, L.L.C. | $21.35 | 2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $19.69 | 2025 | |
| Kyowa Kirin, INC. | $19.03 | 2025 | |
| Daiichi Sankyo INC. | $18.28 | 2024 | Injectafer |
| Fresenius USA Marketing, INC. | $13.80 | 2024 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.